{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:15:03Z","timestamp":1792088103970,"version":"4.4.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[1998,4,1]],"date-time":"1998-04-01T00:00:00Z","timestamp":891388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>From bronchoprovocation studies and investigations of the acute effects of drugs that inhibit leukotrienes (LT), the hypothesis has emerged that leukotrienes are important mediators of airway obstruction and other symptoms in aspirin-intolerant asthma (AIA). However, it has yet not been shown if subjects with AIA respond favorably to clinical treatment with leukotriene inhibitors. Therefore, in a double-blind placebo-controlled crossover study, we examined the effects of 6 wk of treatment with the leukotriene-pathway inhibitor zileuton (600 mg, four times daily) in 40 patients with well-characterized AIA. The treatment was added to existing therapy, which included medium to high doses of inhaled (average daily dose 1,030 \u03bc g of beclomethasone or budesonide) or oral glucocorticosteroids (4 to 25 mg\/d) for all but one of the patients. On top of this treated baseline, there were no significant effects of adding placebo, indicating that their asthma was kept relatively stable. However, there was an acute and chronic improvement in pulmonary function after treatment with zileuton, expressed both as increased FEV1 from baseline compared with placebo, and higher morning and evening peak expiratory flow rate (PEFR) values on zileuton treatment compared with placebo. The improvements occurred despite lower use of rescue bronchodilator with zileuton. Zileuton also diminished nasal dysfunction, which is one of the cardinal signs of AIA. There was a remarkable return of smell, less rhinorrhea, and a trend for less stuffiness and higher nasal inspiratory flow during treatment with zileuton. Zileuton caused a small but distinct reduction of bronchial hyperresponsiveness to histamine and inhibited aspirin-induced bronchoconstriction. Zileuton inhibited urinary excretion of LTE4 but did not change airway reactivity to inhaled LTD4\u2009, supporting that zileuton specifically inhibited leukotriene biosynthesis. The findings indicate that leukotrienes are important mediators of persistent airway obstruction and chronic nasal dysfunction in AIA. The study also suggests that addition of a leukotriene pathway inhibitor such as zileuton may bring about greater control of asthma than what is achieved by treatment with medium to high doses of glucocorticosteroids alone.<\/jats:p>","DOI":"10.1164\/ajrccm.157.4.9707089","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T13:35:05Z","timestamp":1365082505000},"page":"1187-1194","source":"Crossref","is-referenced-by-count":317,"title":["Benefits from Adding the 5-Lipoxygenase Inhibitor Zileuton to Conventional Therapy in Aspirin-intolerant Asthmatics"],"prefix":"10.1093","volume":"157","author":[{"given":"BARBRO","family":"DAHL\u00c9N","sequence":"first","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EWA","family":"NIZANKOWSKA","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDREW","family":"SZCZEKLIK","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"OLLE","family":"ZETTERSTR\u00d6M","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GRAZYNA","family":"BOCHENEK","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARIA","family":"KUMLIN","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LUCYNA","family":"MASTALERZ","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GRAZYNA","family":"PINIS","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LINDA J.","family":"SWANSON","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TERRY I.","family":"BOODHOO","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEPHEN","family":"WRIGHT","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LOUISE M.","family":"DUB\u00c9","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SVEN-ERIK","family":"DAHL\u00c9N","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine at Karolinska Hospital, and Experimental Asthma and Allergy Research at National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland; and Abbott Laboratories, Immunoscience Venture, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[1998,4,1]]},"reference":[{"key":"2026032709145798700_B1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1398-9995.1997.tb01039.x","article-title":"Mechanism of aspirin-induced asthma.","volume":"52","author":"Szczeklik","year":"1997","journal-title":"Allergy"},{"key":"2026032709145798700_B2"},{"key":"2026032709145798700_B3","first-page":"67","article-title":"Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients.","volume":"1","author":"Szczeklik","year":"1975","journal-title":"B.M.J."},{"key":"2026032709145798700_B4"},{"key":"2026032709145798700_B5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0140-6736(93)91073-U","article-title":"Leukotriene E4 causes granulocyte infiltration into asthmatic airways.","volume":"341","author":"Laitinen","year":"1993","journal-title":"Lancet"},{"key":"2026032709145798700_B6","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1164\/ajrccm.155.4.9105062","article-title":"The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma.","volume":"155","author":"Diamant","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026032709145798700_B7","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1164\/ajrccm.155.4.9105085","article-title":"Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism.","volume":"155","author":"Munoz","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026032709145798700_B8","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1183\/09031936.93.06071018","article-title":"The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine\u2013aspirin in aspirin-sensitive asthmatics.","volume":"6","author":"Dahl\u00e9n","year":"1993","journal-title":"Eur. Respir. J."},{"key":"2026032709145798700_B9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1164\/ajrccm.150.1.8025759","article-title":"Inhibition of analgesic-induced asthma by the leukotriene receptor antagonist ONO-1078.","volume":"150","author":"Yamamoto","year":"1994","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026032709145798700_B10","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/ajrccm\/144.4.957","article-title":"The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma.","volume":"144","author":"Christie","year":"1991","journal-title":"Am. Rev. Respir. Dis."},{"key":"2026032709145798700_B11","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1447","article-title":"The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.","volume":"148","author":"Israel","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"2026032709145798700_B12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/thx.49.8.749","article-title":"Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma.","volume":"49","author":"Nasser","year":"1994","journal-title":"Thorax"},{"key":"2026032709145798700_B13","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1025","article-title":"Urinary leukotriene E4 concentrations increase after ASA challenge in ASA-sensitive asthmatic subjects.","volume":"143","author":"Christie","year":"1991","journal-title":"Am. Rev. Respir. Dis."},{"key":"2026032709145798700_B14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/ajrccm\/146.1.96","article-title":"Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics.","volume":"146","author":"Kumlin","year":"1992","journal-title":"Am. Rev. Respir. Dis."},{"key":"2026032709145798700_B15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1164\/ajrccm\/140.1.148","article-title":"Airway responsiveness to histamine and leukotriene E4 in subjects with ASA- induced asthma.","volume":"140","author":"Arm","year":"1989","journal-title":"Am. Rev. Respir. Dis."},{"key":"2026032709145798700_B16","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/thx.48.12.1205","article-title":"Effect of the leukotriene-antagonist MK-0679 on baseline pulmonary function in aspirin-sensitive asthmatics.","volume":"48","author":"Dahl\u00e9n","year":"1993","journal-title":"Thorax"},{"key":"2026032709145798700_B17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(95)12297-4","article-title":"Zileuton.","volume":"348","author":"McGill","year":"1996","journal-title":"Lancet"},{"key":"2026032709145798700_B18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2222.1986.tb01960.x","article-title":"Effect of LTD4 on nasal mucosal blood flow, nasal airway resistance and nasal secretions in humans.","volume":"16","author":"Bisgaard","year":"1986","journal-title":"Clin. Allergy"},{"key":"2026032709145798700_B19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1164\/ajrccm\/136.2.357","article-title":"Behaviour and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen- induced rhinitis.","volume":"136","author":"Miadonna","year":"1987","journal-title":"Am. Rev. Respir. Dis."},{"key":"2026032709145798700_B20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2222.1995.tb01079.x","article-title":"Validation and application of a new simple strategy for measurements of leukotriene E4 in human urine.","volume":"25","author":"Kumlin","year":"1995","journal-title":"Clin. Exp. Allergy"},{"key":"2026032709145798700_B21","first-page":"103","article-title":"Pharmacokinetics, safety and ability to diminish leukotriene synthesis by zileuton, an inhibitor of the 5-lipoxygenase.","volume":"35(Suppl.)","author":"Rubin","year":"1991","journal-title":"Agents Actions"},{"key":"2026032709145798700_B22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2125.1979.tb05903.x","article-title":"The two-period cross-over clinical trial.","volume":"8","author":"Hills","year":"1979","journal-title":"Br. J. Clin. Pharmac."},{"key":"2026032709145798700_B23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(94)92996-3","article-title":"Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid.","volume":"344","author":"Greening","year":"1994","journal-title":"Lancet"},{"key":"2026032709145798700_B24","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1164\/ajrccm.153.5.8630590","article-title":"Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.","volume":"153","author":"Woolcock","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026032709145798700_B25","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJM199012203232506","article-title":"Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor.","volume":"323","author":"Knapp","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"2026032709145798700_B26","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/0091-6749(94)90123-6","article-title":"Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.","volume":"94","author":"Fischer","year":"1994","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026032709145798700_B27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/jama.1996.03530360041036","article-title":"Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma.","volume":"275","author":"Israel","year":"1996","journal-title":"J.A.M.A."},{"key":"2026032709145798700_B28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0091-6749(96)80002-9","article-title":"Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial.","volume":"98","author":"Liu","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026032709145798700_B29","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1164\/ajrccm.154.6.8970343","article-title":"Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics.","volume":"154","author":"Szczeklik","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026032709145798700_B30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.7326\/0003-4819-119-11-199312010-00001","article-title":"The effect of inhibition of 5-lipoxygenase by Zileuton in mild-to-moderate asthma.","volume":"119","author":"Israel","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"2026032709145798700_B31","doi-asserted-by":"crossref","first-page":"6974","DOI":"10.1073\/pnas.87.18.6974","article-title":"Inhibition of eicosanoid synthesis by glucocorticoids in humans.","volume":"87","author":"Sebalt","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026032709145798700_B32","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/ajrccm\/147.6_Pt_1.1472","article-title":"Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion.","volume":"147","author":"O'Shaughnessy","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"2026032709145798700_B33","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1164\/ajrccm.149.4.8143061","article-title":"Effect of oral prednisone on airway inflammatory mediators in atopic asthma.","volume":"149","author":"Dworski","year":"1994","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026032709145798700_B34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1432-1033.1997.00112.x","article-title":"Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells.","volume":"146","author":"Riddick","year":"1997","journal-title":"Eur. J. Biochem."},{"key":"2026032709145798700_B35","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1164\/ajrccm.155.4.9105060","article-title":"Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid.","volume":"155","author":"Tamaoki","year":"1997","journal-title":"Am. Respir. Crit. Care Med."}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/157\/4\/1187\/67447655\/ajrccm_157_4_1187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/157\/4\/1187\/67447655\/ajrccm_157_4_1187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:15:06Z","timestamp":1774617306000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/157\/4\/1187\/8531230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,4,1]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[1998,4,1]]},"published-print":{"date-parts":[[1998,4,1]]}},"URL":"https:\/\/doi.org\/10.1164\/ajrccm.157.4.9707089","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1998,4]]},"published":{"date-parts":[[1998,4,1]]}}}